Patents Examined by Stacy B. Chen
  • Patent number: 11541113
    Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: January 3, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John
  • Patent number: 11542527
    Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: January 3, 2023
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventor: Biao He
  • Patent number: 11512327
    Abstract: The invention provides compositions and methods for the preparation, manufacture, formulation and therapeutic use of adeno-associated virus (AAV) particles for the prevention and/or treatment of diseases.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 29, 2022
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Holger Patzke, Jinzhao Hou, Mathieu E. Nonnenmacher, Martin Goulet, Todd Carter
  • Patent number: 11510977
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: November 29, 2022
    Assignee: Suzhou Abogen Biosciences Co., Ltd.
    Inventor: Bo Ying
  • Patent number: 11510973
    Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: November 29, 2022
    Assignee: GRITSTONE BIO, INC.
    Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
  • Patent number: 11504421
    Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: November 22, 2022
    Assignee: GRITSTONE BIO, INC.
    Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
  • Patent number: 11484586
    Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 1, 2022
    Assignees: Thomas Jefferson University, ICAHN School of Medicine at Mount Sinai
    Inventors: Matthias Schnell, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
  • Patent number: 11435351
    Abstract: Compositions and methods for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and frozen. Upon thawing aliquots these cells are activated by exposure to a series of dilutions of q vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 6, 2022
    Assignee: BioMadison, Inc.
    Inventor: Ward C Tucker
  • Patent number: 11434261
    Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: September 6, 2022
    Assignee: Hawaii Biotech Inc.
    Inventor: David E. Clements
  • Patent number: 11419929
    Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: August 23, 2022
    Assignee: GRITSTONE BIO, INC.
    Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
  • Patent number: 11414677
    Abstract: Disclosed herein are methods of performing continuous directed evolution in complex biological systems, including metazoan cells. These methods include the infection of engineered, non-naturally occurring metazoan cells with engineered, non-naturally occurring DNA viruses. The generation of infectious viruses that can infect new cells depends on the evolution of a gene of interest which is driven by an error-prone adenoviral polymerase. Also disclosed herein, are the compositions of engineered, non-naturally occurring metazoan cells and engineered, non-naturally occurring DNA viruses that function as components in the continuous directed evolution methodologies.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: August 16, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Matthew D. Shoulders, Chet Berman, Christopher Lawrence Moore, Louis John Papa, Samuel Joseph Hendel
  • Patent number: 11406699
    Abstract: The present invention provides modified alphaviruses and compositions, methods, and kits for preparing and using them to elicit an immune response to an alphavirus in a subject.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 9, 2022
    Assignee: George Mason University
    Inventors: Kylene Wesley Kehn-Hall, Brian D. Carey, Ivan V. Akhrymuk, Caitlin W. Lehman
  • Patent number: 11407816
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: August 9, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Patent number: 11407817
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: August 9, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Z. Wec, Laura Walker
  • Patent number: 11385148
    Abstract: An infectious disease screening system (1) for screening for infectious diseases, such as COVID-19 disease. The system comprises an ultrasonic transducer (49) for generating ultrasonic waves to lyse cells in a biological sample. The system (1) comprises a controller which controls the ultrasonic transducer (49) to oscillate at an optimum frequency for cell lysis, a PCR apparatus (16) which receives and amplifies the DNA from the sample; and a detection apparatus (70) which detects the presence of an infectious disease in the amplified DNA and provides an output which is indicative of whether or not the detection arrangement (70) detects the presence of an infectious disease in the amplified DNA.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: July 12, 2022
    Assignee: Shaheen Innovations Holding Limited
    Inventors: Imad Lahoud, Mohammed Alshaiba Saleh Ghannam Almazrouei, Sajid Bhatti, Jeff Machovec, Clement Lamoureux
  • Patent number: 11382968
    Abstract: Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: July 12, 2022
    Assignee: Altimmune Inc.
    Inventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
  • Patent number: 11357795
    Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 14, 2022
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Patent number: 11351245
    Abstract: A buffer free, acid stable, low dose volume rotavirus vaccine is disclosed. The vaccine is available in dose volume of less than 1 ml per dose for oral administration and it is without any buffer. The vaccine also does not require pre or post administration of any antacid at the time of oral administration of the vaccine to the subject to neutralize the stomach acid. The vaccine exemplifies nominal drop in vaccine titer at pH 2-4 for a time span of 30 minutes. The vaccine is stable at ?20° C. for at least 60 months.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: June 7, 2022
    Assignee: Bharat Biotech International Limited
    Inventors: Krishna Mohan Vadrevu, Sai Devarajulu Prasad, Krishna Murthy Ella
  • Patent number: 11351240
    Abstract: The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 7, 2022
    Assignee: Katholieke Universiteit Leuven
    Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts, Michael Alexander Schmid
  • Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet